Community Research and Development Information Service - CORDIS

H2020

QUIBIM Report Summary

Project ID: 736722

Periodic Reporting for period 1 - QUIBIM (QUantitative Imaging Biomarkers Medice)

Reporting period: 2016-08-01 to 2016-12-31

Summary of the context and overall objectives of the project

At present, most of the imaging diagnoses are still carried out by means of qualitative evaluations of the medical professional. Although such assessments are mostly accurate, there is a vast amount of data in radiological images that are not accessible to the human eye. Despite the fact that research groups from around the world have significantly deepened in the quantitative analysis of medical imaging, even today the technological transfer between the advances made in research and patients as the end user beneficiary of these advances remains a minority.

QUIBIM Precision® responds to this technological challenge by integrating the image biomarkers within the radiological workflow in a simple and intuitive way that facilitates their adoption by all the value chain, from the health and research staff to the managers of clinical analysis. QUIBIM Precision® is the world's first cloud platform that allows any physician, doctor or specialist to accurately, automatically and medically certified analysis of medical images.

It is a disruptive product both for its technology and for the business model and revolution in prices and delivery times that it entails. Currently, the cost of quantitatively analyzing a medical image (eg, an x-ray) through the traditional method: sending to a laboratory entails costs of between € 200 and € 1,000 per image, and the results are obtained between 3 and 4 days After laboratory. QUIBIM can perform this same analysis in onyl 5 minutes and for 45€/analysis.

Our overall objective for this Phase is to finalize the innovations needed to make QUIBIM a complete and world-class product and lead the emerging market of quantitative analytics in medical images.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During the execution of the Phase 1 project 1) we have carried out a detailed assessment of QUIBIM’s target markets; we have also interviewed and collected commitment to the project from relevant organisations within the medical diagnosis industry that can leverage the commercialization and internationalization of QUIBIM in its route to market; 2) we have analysed the conditions for FDA certification, the potential of applying for new patents for new imaging biomarkers we are developing and the general IPR of our software; 3) we have carried out an intensive research of key providers in the areas of Data Visualization and High Performance Computing; 4) we have created throughout financial estimations for QUIBIM as a high-growth business; and 5) we have built a clear fully-market oriented innovation roadmap for Phase 2 and beyond.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

We aim at creating a high impact at different levels, mainly in the ICT Industry and the Public and private health systems:
- QUIBIM contributes to accelerate the European up-take of ICT and Cloud Computing technologies by industry and public sector (which includes private and public hospitals). This has been identified as a key objective within the Digital Agenda for Europe (DAE) towards year 2020, for which a specific European Cloud Computing Strategy has been put in place.
-QUIBIM is part of the actors carrying out the implementation and wider deployment of interoperable Electronic Health Records (EHR) in Europe, which has been identified as one of the highest priorities in the European eHealth action plan 2012-2020. To this end, one of the key priorities identified by relevant actors within the eHealth industry such as the European Society of Radiology is “detecting clinically meaningful biomarkers”. EHR are becoming an increasingly common data source for understanding serious diseases and clinical risks, and QUIBIM can play a crucial role in it providing the most advance platform in quantitative imaging biomarkers.
-QUIBIM helps medical organizations make and efficient use of resources and achieve a better value for money, in line with the objectives stated in different EC Communications which encourage more cost-effective provision of health services by adopting technologies with potential to improve efficiency and productivity.

Furthermore, QUIBIM 1) Increases clinical availability and exploitation of biomarkers for the benefit of the patient; 2) facilitates the entry of improved diagnostics in the clinic and the market; 3) contributes to the sustainability of health care systems; 4) enhance the availability and value of medical data by combining and transferring new and existing knowledge; 5) leverages private investment in clinical validation and and/or follow-up investments.

Related information

Record Number: 196509 / Last updated on: 2017-03-29
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top